JP2012505891A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505891A5
JP2012505891A5 JP2011532175A JP2011532175A JP2012505891A5 JP 2012505891 A5 JP2012505891 A5 JP 2012505891A5 JP 2011532175 A JP2011532175 A JP 2011532175A JP 2011532175 A JP2011532175 A JP 2011532175A JP 2012505891 A5 JP2012505891 A5 JP 2012505891A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
halogen
pyridinyl
alkoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505891A (ja
JP5529876B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060436 external-priority patent/WO2010045188A1/en
Publication of JP2012505891A publication Critical patent/JP2012505891A/ja
Publication of JP2012505891A5 publication Critical patent/JP2012505891A5/ja
Application granted granted Critical
Publication of JP5529876B2 publication Critical patent/JP5529876B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532175A 2008-10-17 2009-10-13 Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物 Expired - Fee Related JP5529876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10620708P 2008-10-17 2008-10-17
US61/106,207 2008-10-17
PCT/US2009/060436 WO2010045188A1 (en) 2008-10-17 2009-10-13 Heteroaryl substituted indole compounds useful as mmp-13 inhibitors

Publications (3)

Publication Number Publication Date
JP2012505891A JP2012505891A (ja) 2012-03-08
JP2012505891A5 true JP2012505891A5 (enExample) 2012-11-29
JP5529876B2 JP5529876B2 (ja) 2014-06-25

Family

ID=41508906

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532175A Expired - Fee Related JP5529876B2 (ja) 2008-10-17 2009-10-13 Ｍｍｐ−１３阻害剤として有用なヘテロアリール置換インドール化合物

Country Status (5)

Country Link
US (1) US8785489B2 (enExample)
EP (1) EP2340243B1 (enExample)
JP (1) JP5529876B2 (enExample)
CA (1) CA2738929A1 (enExample)
WO (1) WO2010045188A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344480A1 (en) 2008-10-15 2011-07-20 Boehringer Ingelheim International GmbH Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
WO2010045188A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
CA2743146A1 (en) 2008-11-17 2010-05-20 Boehringer Ingelheim International Gmbh Heteroaryl diamide compounds useful as mmp-13 inhibitors
CA2771026A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
AU2012285931B2 (en) 2011-07-15 2017-01-12 Cellzome Limited Novel substituted indole derivatives as gamma secretase modulators
WO2013033085A1 (en) * 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US10266490B2 (en) * 2012-03-16 2019-04-23 Georgetown University Radioprotector compounds
KR102338461B1 (ko) 2013-11-13 2021-12-13 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제 억제제의 제조 방법
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
WO2016026078A1 (en) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR20180086247A (ko) 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
US10550091B2 (en) 2016-03-25 2020-02-04 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
ES2863474T3 (es) 2016-07-30 2021-10-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con dimetoxifenilo como inhibidores de TLR7, TLR8 o TLR9
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
JP7287964B2 (ja) 2017-12-15 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールエーテル化合物
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
SG11202005700SA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
SG11202005696YA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
ES2965182T3 (es) 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
MX2020006014A (es) 2017-12-20 2020-08-17 Bristol Myers Squibb Co Compuestos de diazaindol.
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
CN112839648B (zh) 2018-06-07 2025-04-04 达萨玛治疗公司 Sarm1抑制剂
EP3628669A1 (en) * 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
KR102911861B1 (ko) 2018-10-24 2026-01-12 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 이량체 화합물
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
ES2987832T3 (es) 2019-05-09 2024-11-18 Bristol Myers Squibb Co Compuestos de benzimidazolona sustituidos
US12448395B2 (en) 2019-10-01 2025-10-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
WO2021067657A1 (en) 2019-10-04 2021-04-08 Bristol-Myers Squibb Company Substituted carbazole compounds
KR20220097434A (ko) * 2019-11-01 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 톨 수용체 억제제로서의 치환된 피라졸 화합물
TW202227432A (zh) 2020-08-19 2022-07-16 美商必治妥美雅史谷比公司 可做為tlr9抑制劑之經取代雙環化合物
AU2021329323A1 (en) 2020-08-19 2023-03-16 Bristol-Myers Squibb Company 1H-benzo(d)imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis
CN116947821B (zh) * 2022-04-20 2025-10-17 成都肯迪特生物医药科技有限公司 一种化合物及其在制备jak激酶抑制剂中的用途
US12516051B1 (en) 2024-09-30 2026-01-06 St. Jude Children's Research Hospital, Inc. Small molecule degraders and fluorescent probes of PXR

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151380A (ja) * 1994-11-29 1996-06-11 Kyorin Pharmaceut Co Ltd ビス（トリフルオロメチルピロロインドールカルボン酸エステル）誘導体及びその製造方法
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
AU2001278508A1 (en) 2000-07-31 2002-02-13 Smithkline Beecham P.L.C. Carboxamide compounds and their use as antagonists of a human 11cby receptor
GB0018758D0 (en) 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
AU2001277621A1 (en) 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
WO2003020699A2 (en) * 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
JP4901102B2 (ja) * 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
DE10229070A1 (de) 2002-06-28 2004-01-15 Merck Patent Gmbh Phenylderivate 5
ATE473974T1 (de) 2003-05-21 2010-07-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase
CN101031539A (zh) 2003-08-14 2007-09-05 旭化成制药株式会社 取代的芳基链烷酸衍生物及其用途
MX2007000669A (es) 2004-07-20 2007-05-23 Siena Biotech Spa Moduladores de receptores acetilcolina nicotinicos alfa 7 y sus usos terapeuticos.
KR20070100888A (ko) * 2004-12-07 2007-10-12 토야마 케미칼 컴퍼니 리미티드 신규의 안트라닐산 유도체 또는 그 염
WO2006066879A2 (en) 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
EP1860098B1 (en) * 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
US20060235037A1 (en) * 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
SG140147A1 (en) 2005-08-19 2008-03-28 Aventis Pharma Inc Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
EP2344480A1 (en) 2008-10-15 2011-07-20 Boehringer Ingelheim International GmbH Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
WO2010045188A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
CA2743146A1 (en) 2008-11-17 2010-05-20 Boehringer Ingelheim International Gmbh Heteroaryl diamide compounds useful as mmp-13 inhibitors

Similar Documents

Publication Publication Date Title
JP2012505891A5 (enExample)
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
CN101784532B (zh) Hiv逆转录酶抑制剂
JP2013518110A5 (enExample)
JP2013505969A5 (enExample)
JP2009530283A5 (enExample)
JP2010510231A5 (enExample)
JP2012507566A5 (enExample)
CA2451981A1 (en) 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
JP2012505234A5 (enExample)
JP2008535903A5 (enExample)
JP2016190843A5 (enExample)
JP2007524696A5 (enExample)
JP2016196492A5 (enExample)
JP2011513305A5 (enExample)
JP2013544854A5 (enExample)
JP2015051994A5 (enExample)
BRPI0807581A2 (pt) Moduladores de propriedades farmacocinéticas de produtos terapêuticos
RU2008140943A (ru) Аналоги тиазолидиндиона
JP2010519260A5 (enExample)
JP2017508795A5 (enExample)
RU2015147447A (ru) Производные доластатина 10 и ауристатинов
JP2017214387A5 (enExample)
RU2012136624A (ru) Фармацевтические композиции для лечения боли и других показаний
JP2017532360A5 (enExample)